Obsidian Therapeutics Q3 2026 Results: Net Loss of $50.7M, Loss Widens
Obsidian Therapeutics is a clinical-stage biopharmaceutical company focused on developing amsoki-cel (formerly OBX-115). As of November 9, 2026, the company had 61,774,046 shares of common stock outstanding and continues to incur significant financial losses to fund its research and development programs.
- Key figure
- Net loss $50.7M